InsiderTrades.com logo
Breaking News: Tesla headed to $500…
From WealthPress   |   Ad
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
So to claim your free digital copy today, simply follow this link and enter your email address. 
Kevin Bitterman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Kevin Bitterman Biography and Net Worth

Director of Akero Therapeutics
Kevin Bitterman focuses on creating and investing in companies that translate groundbreaking science into innovative medicines.

Kevin serves on the board of Navitor Pharmaceuticals. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic, and Visterra, and co-founded Genocea Biosciences (NASDAQ: GNCA). He previously served as a director of InSeal Medical, Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics, Taris Biomedical (acquired by Allergan), and Vets First Choice, among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004.

Kevin is active in the local life science and healthcare start-up community, serving on the Scientific Advisory Board of the Massachusetts Life Sciences Center (MLSC), and as Board Chair of the New England Venture Capital Association (NEVCA). He received a BA in biology, summa cum laude, from Rutgers University before completing his PhD in genetics at Harvard Medical School. He has published numerous scientific articles, and is an inventor on several issued patents.

What is Kevin Bitterman's net worth?

The estimated net worth of Kevin Bitterman is at least $6.15 million as of January 23rd, 2024. Mr. Bitterman owns 198,326 shares of Akero Therapeutics stock worth more than $6,154,056 as of November 20th. This net worth approximation does not reflect any other assets that Mr. Bitterman may own. Learn More about Kevin Bitterman's net worth.

How do I contact Kevin Bitterman?

The corporate mailing address for Mr. Bitterman and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at [email protected]. Learn More on Kevin Bitterman's contact information.

Has Kevin Bitterman been buying or selling shares of Akero Therapeutics?

Kevin Bitterman has not been actively trading shares of Akero Therapeutics in the last ninety days. Most recently, Kevin Bitterman sold 17,489 shares of the business's stock in a transaction on Tuesday, June 1st. The shares were sold at an average price of $26.28, for a transaction totalling $459,610.92. Learn More on Kevin Bitterman's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, Akero Therapeutics insiders bought shares 2 times. They purchased a total of 150,000 shares worth more than $2,828,000.00. During the last twelve months, insiders at the sold shares 41 times. They sold a total of 777,704 shares worth more than $22,728,155.84. The most recent insider tranaction occured on November, 15th when insider Catriona Yale sold 9,061 shares worth more than $251,261.53. Insiders at Akero Therapeutics own 7.9% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 11/15/2024.

Kevin Bitterman Insider Trading History at Akero Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2021Sell17,489$26.28$459,610.92View SEC Filing Icon  
10/9/2020Sell13,000$28.93$376,090.00View SEC Filing Icon  
See Full Table

Kevin Bitterman Buying and Selling Activity at Akero Therapeutics

This chart shows Kevin Bitterman's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $31.16
Low: $30.68
High: $31.23

50 Day Range

MA: $29.63
Low: $25.62
High: $35.28

2 Week Range

Now: $31.16
Low: $15.32
High: $37.00

Volume

35,764 shs

Average Volume

864,742 shs

Market Capitalization

$2.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Trump won. Buy this coin now.
From Weiss Ratings   |   Ad
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
This could be his favorite coin.